JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $177 from $176 and keeps an Overweight rating on the shares. The firm increased Crenessity estimates after surveying 25 endocrinologists. JPMorgan is “encouraged” by the survey results which suggest “strong uptake” of Crenessity over the next year across key settings and physician populations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine initiated with an Outperform at Wolfe Research
- Neurocrine price target lowered to $140 from $169 at Truist
- Neurocrine post-earnings selloff overdone, says JPMorgan
- Neurocrine Biosciences Earnings Call Highlights Growth Momentum
- Neurocrine price target lowered to $177 from $180 at RBC Capital